Abdominal Fat and Metabolic Health Markers but Not PNPLA3 Genotype Predicts Liver Fat Accumulation in Response to Excess Intake of Energy and Saturated Fat in Healthy Individuals

Fredrik Rosqvist, Marju Orho-Melander, Joel Kullberg, David Iggman, Hans-Erik Johansson, Jonathan Cedernaes, Håkan Ahlström, Ulf Risérus, Fredrik Rosqvist, Marju Orho-Melander, Joel Kullberg, David Iggman, Hans-Erik Johansson, Jonathan Cedernaes, Håkan Ahlström, Ulf Risérus

Abstract

Background: Saturated fat (SFA) has consistently been shown to increase liver fat, but the response appears variable at the individual level. Phenotypic and genotypic characteristics have been demonstrated to modify the hypercholesterolemic effect of SFA but it is unclear which characteristics that predict liver fat accumulation in response to a hypercaloric diet high in SFA. Objective: To identify predictors of liver fat accumulation in response to an increased intake of SFA. Design: We pooled our two previously conducted double-blind randomized trials (LIPOGAIN and LIPOGAIN-2, clinicaltrials.gov NCT01427140 and NCT02211612) and used data from the n = 49 metabolically healthy men (n = 32) and women (n = 17) randomized to a hypercaloric diet through addition of SFA-rich muffins for 7-8 weeks. Associations between clinical and metabolic variables at baseline and changes in liver fat during the intervention were analyzed using Spearman rank correlation. Linear regression was used to generate a prediction model. Results: Liver fat increased by 33% (IQR 5.4-82.7%; P < 0.0001) in response to excess energy intake and this was not associated (r = 0.17, P = 0.23) with the increase in body weight (1.9 kg; IQR 1.1-2.9 kg). Liver fat accumulation was similar (P = 0.28) in carriers (33%, IQR 14-79%) and non-carriers (33%, IQR -11 to +87%) of the PNPLA3-I148M variant. Baseline visceral and liver fat content, as well as levels of the liver enzyme γ-glutamyl transferase (GT), were the strongest positive predictors of liver fat accumulation-in contrast, adiponectin and the fatty acid 17:0 in adipose tissue were the only negative predictors in univariate analyses. A regression model based on eight clinical and metabolic variables could explain 81% of the variation in liver fat accumulation. Conclusion: Our results suggest there exists a highly inter-individual variation in the accumulation of liver fat in metabolically healthy men and women, in response to an increased energy intake from SFA and carbohydrates that occurs over circa 2 months. This marked variability in liver fat accumulation could largely be predicted by a set of clinical (e.g., GT and BMI) and metabolic (e.g., fatty acids, HOMA-IR, and adiponectin) variables assessed at baseline.

Keywords: NAFLD; fatty acids; liver fat; overfeeding; saturated fat.

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Rosqvist, Orho-Melander, Kullberg, Iggman, Johansson, Cedernaes, Ahlström and Risérus.

Figures

Figure 1
Figure 1
(A) Correlation between the change in body weight and change in liver fat accumulation (n = 49), (B) changes in liver fat content and body weight at the individual level, sorted according to the relative change in liver fat content (n = 49).
Figure 2
Figure 2
Clinical and metabolic predictors of liver fat accumulation in univariate analyses. ALT, alanine aminotransferase; BMI, body mass index; HOMA-IR, homeostatic model assessment of insulin resistance; LDL, low density lipoprotein; HDL, high density lipoprotein; Apo, apolipoprotein; VAT, visceral adipose tissue; SAT, subcutaneous adipose tissue; BP, blood pressure; FGF21, fibroblast growth factor; TSH, thyroid stimulating hormone; PCSK9, proprotein convertase subtilisin/kexin type 9; CRP, C-reactive protein.
Figure 3
Figure 3
Fatty acid abundances at baseline as predictors of liver fat accumulation in univariate analyses. (A) Plasma cholesterol esters, (B) plasma phospholipids, (C) subcutaneous adipose tissue. The bars represent the Spearman rank correlation (written beside the bars). SCD; stearoyl-CoA desaturase; D6D, delta-6 desaturase; D5D, delta-5 desaturase.
Figure 4
Figure 4
Actual by predicted plot (linear regression) for change in liver fat content and the eight individual predictors used in the regression model. All variables significantly associated with liver fat accumulation in univariate analyses were initially included in the regression model. To avoid multicollinearity, the variable list was sequentially culled based on the highest variance inflation factor (VIF) until all included variables had a VIF P-value until all included variables had a P < 0.01. AT, adipose tissue; BP, blood pressure; VIF, variance inflation factor; HOMA-IR, homeostatic model assessment of insulin resistance; BMI, body mass index.

References

    1. Tilg H, Moschen AR, Roden M. NAFLD and diabetes mellitus. Nat Rev Gastroenterol Hepatol. (2017) 14:32–42. 10.1038/nrgastro.2016.147
    1. Stols-Goncalves D, Hovingh GK, Nieuwdorp M, Holleboom AG. NAFLD and atherosclerosis: two sides of the same dysmetabolic coin? Trends Endocrinol Metab. (2019) 30:891–902. 10.1016/j.tem.2019.08.008
    1. Sookoian S, Pirola CJ. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology. (2011) 53:1883–94. 10.1002/hep.24283
    1. Parry SA, Hodson L. Influence of dietary macronutrients on liver fat accumulation and metabolism. J Invest Med. (2017) 65:1102–15. 10.1136/jim-2017-000524
    1. Hodson L, Rosqvist F, Parry SA. The influence of dietary fatty acids on liver fat content and metabolism. Proc Nutr Soc. (2019) 79:30–41. 10.1017/S0029665119000569
    1. Bjermo H, Iggman D, Kullberg J, Dahlman I, Johansson L, Persson L, et al. . Effects of n-6 PUFAs compared with SFAs on liver fat, lipoproteins, and inflammation in abdominal obesity: a randomized controlled trial. Am J Clin Nutr. (2012) 95:1003–12. 10.3945/ajcn.111.030114
    1. Rosqvist F, Iggman D, Kullberg J, Jonathan Cedernaes J, Johansson HE, Larsson A, et al. . Overfeeding polyunsaturated and saturated fat causes distinct effects on liver and visceral fat accumulation in humans. Diabetes. (2014) 63:2356–68. 10.2337/db13-1622
    1. Rosqvist F, Kullberg J, Stahlman M, Cedernaes J, Heurling K, Johansson HE, et al. . Overeating saturated fat promotes fatty liver and ceramides compared with polyunsaturated fat: a randomized trial. J Clin Endocrinol Metab. (2019) 104:6207–19. 10.1210/jc.2019-00160
    1. Della Pepa G, Vetrani C, Brancato V, Vitale M, Monti S, Annuzzi G, et al. . Effects of a multifactorial ecosustainable isocaloric diet on liver fat in patients with type 2 diabetes: randomized clinical trial. BMJ Open Diabetes Res Care. (2020) 8:e001342. 10.1136/bmjdrc-2020-001342
    1. Parry SA, Rosqvist F, Mozes FE, Cornfield T, Hutchinson M, Piche ME, et al. . Intrahepatic fat and postprandial glycemia increase after consumption of a diet enriched in saturated fat compared with free sugars. Diabetes Care. (2020) 43:1134–41. 10.2337/dc19-2331
    1. Luukkonen PK, Sadevirta S, Zhou Y, Kayser B, Ali A, Ahonen L, et al. Saturated fat is more metabolically harmful for the human liver than unsaturated fat or simple sugars. Diabetes Care. (2018) 41:1732–9. 10.2337/dc18-0071
    1. Winters-van Eekelen E, Verkouter I, Peters HPF, Alssema M, de Roos BG, Schrauwen-Hinderling VB, et al. . Effects of dietary macronutrients on liver fat content in adults: a systematic review and meta-analysis of randomized controlled trials. Eur J Clin Nutr. (2020). 10.1038/s41430-020-00778-1. [Epub ahead of print].
    1. Meex RCR, Blaak EE. Mitochondrial dysfunction is a key pathway that links saturated fat intake to the development and progression of NAFLD. Mol Nutr Food Res. (2020) 2020:e1900942. 10.1002/mnfr.201900942
    1. Jian C, Luukkonen P, Sädevirta S, Yki-Järvinen H, Salonen A. Impact of short-term overfeeding of saturated or unsaturated fat or sugars on the gut microbiota in relation to liver fat in obese and overweight adults. Clin Nutr. (2020). 10.1016/j.clnu.2020.05.008. [Epub ahead of print].
    1. Parry S, Rosqvist F, Cornfield T, Barrett A, Hodson L. Oxidation of dietary linoleate occurs to a greater extent than dietary palmitate in vivo in humans. Clin Nutr. (2020). 10.1016/j.clnu.2020.07.013. [Epub ahead of print].
    1. Sundfør TM, Svendsen M, Heggen E, Dushanov S, Klemsdal TO, Tonstad S. BMI modifies the effect of dietary fat on atherogenic lipids: a randomized clinical trial. Am J Clin Nutr. (2019) 110:832–41. 10.1093/ajcn/nqz113
    1. Denke MA, Adams-Huet B, Nguyen AT. Individual cholesterol variation in response to a margarine- or butter-based diet: a study in families. JAMA. (2000) 284:2740–7. 10.1001/jama.284.21.2740
    1. Cornier MA, Donahoo WT, Pereira R, Gurevich I, Westergren R, Enerback S, et al. . Insulin sensitivity determines the effectiveness of dietary macronutrient composition on weight loss in obese women. Obes Res. (2005) 13:703–9. 10.1038/oby.2005.79
    1. Yubero-Serrano EM, Delgado-Lista J, Tierney AC, Perez-Martinez P, Garcia-Rios A, Alcala-Diaz JF, et al. . Insulin resistance determines a differential response to changes in dietary fat modification on metabolic syndrome risk factors: the LIPGENE study. Am J Clin Nutr. (2015) 102:1509–17. 10.3945/ajcn.115.111286
    1. Fabbrini E, Yoshino J, Yoshino M, Magkos F, Tiemann Luecking C, Samovski D, et al. . Metabolically normal obese people are protected from adverse effects following weight gain. J Clin Invest. (2015) 125:787–95. 10.1172/JCI78425
    1. Yki-Jarvinen H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol. (2014) 2:901–10. 10.1016/S2213-8587(14)70032-4
    1. Forouhi NG, Koulman A, Sharp SJ, Imamura F, Kroger J, Schulze MB, et al. . Differences in the prospective association between individual plasma phospholipid saturated fatty acids and incident type 2 diabetes: the EPIC-InterAct case-cohort study. Lancet Diabetes Endocrinol. (2014) 2:810–8. 10.1016/S2213-8587(14)70146-9
    1. Fretts AM, Mozaffarian D, Siscovick DS, King IB, McKnight B, Psaty BM, et al. . Associations of plasma phospholipid SFAs with total and cause-specific mortality in older adults differ according to SFA chain length. J Nutr. (2016) 146:298–305. 10.3945/jn.115.222117
    1. Risérus U, Marklund M. Milk fat biomarkers and cardiometabolic disease. Curr Opin Lipidol. (2017) 28:46–51. 10.1097/MOL.0000000000000381
    1. Bokor S, Dumont J, Spinneker A, Gonzalez-Gross M, Nova E, Widhalm K, et al. . Single nucleotide polymorphisms in the FADS gene cluster are associated with delta-5 and delta-6 desaturase activities estimated by serum fatty acid ratios. J Lipid Res. (2010) 51:2325–33. 10.1194/jlr.M006205
    1. Schulze M, Minihane A, Saleh R, Risérus U. Intake and metabolism of n-3 and n-6 PUFA: nutritional implications for cardiometabolic diseases. Lancet Diabetes Endocrinol. (2020) 8:915–930. 10.1016/S2213-8587(20)30148-0
    1. Luukkonen PK, Nick A, Hölttä-Vuori M, Thiele C, Isokuortti E, Lallukka-Brück S, et al. . Human PNPLA3-I148M variant increases hepatic retention of polyunsaturated fatty acids. JCI Insight. (2019) 4:e127902. 10.1172/jci.insight.127902
    1. Luukkonen PK, Zhou Y, Sadevirta S, Leivonen M, Arola J, Oresic M, et al. . Hepatic ceramides dissociate steatosis and insulin resistance in patients with non-alcoholic fatty liver disease. J Hepatol. (2016) 64:1167–75. 10.1016/j.jhep.2016.01.002
    1. Qadri S, Lallukka-Brück S, Luukkonen PK, Zhou Y, Gastaldelli A, Orho-Melander M, et al. . The PNPLA3-I148M variant increases polyunsaturated triglycerides in human adipose tissue. Liver Int. (2020) 40:2128–38. 10.1111/liv.14507
    1. Sobrecases H, Lê KA, Bortolotti M, Schneiter P, Ith M, Kreis R, et al. . Effects of short-term overfeeding with fructose, fat and fructose plus fat on plasma and hepatic lipids in healthy men. Diabetes Metab. (2010) 36:244–6. 10.1016/j.diabet.2010.03.003

Source: PubMed

3
Abonnieren